RU-58668
A detailed overview of the compound RU-58668
RU-58668 is a nonsteroidal antiestrogen compound that has been studied for its potential use in the treatment of hormone-dependent cancers, such as breast cancer. It is a derivative of the well-known antiestrogen RU-486 (mifepristone), but it acts through different mechanisms.
Mechanism of Action[edit | edit source]
RU-58668 functions primarily as an antiestrogen by binding to the estrogen receptor (ER) and inhibiting its activity. Unlike other selective estrogen receptor modulators (SERMs) such as tamoxifen, RU-58668 does not exhibit partial agonist activity. Instead, it acts as a pure antagonist, blocking the effects of estrogen in tissues that express the estrogen receptor.
The compound achieves its effects by preventing the estrogen receptor from binding to DNA and activating the transcription of estrogen-responsive genes. This inhibition can lead to a decrease in the proliferation of estrogen-dependent cancer cells.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of RU-58668 has been studied in preclinical models. It is known to have a high affinity for the estrogen receptor, which contributes to its potent antiestrogenic effects. However, detailed information on its absorption, distribution, metabolism, and excretion in humans is limited, as it has not been widely used in clinical practice.
Clinical Applications[edit | edit source]
RU-58668 has been primarily investigated in the context of breast cancer treatment. Its ability to act as a pure antiestrogen makes it a candidate for cases where other treatments, such as tamoxifen, may not be effective due to their partial agonist activity.
Research and Development[edit | edit source]
Research on RU-58668 has been conducted to explore its potential benefits and limitations. Studies have focused on its efficacy in reducing tumor growth in estrogen-dependent cancers and its safety profile. However, as of the latest updates, RU-58668 has not been approved for clinical use, and further research is needed to fully understand its therapeutic potential.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
